Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content, as replacement therapy for people two years of age and older with primary immunodeficiency (PI). As a ready-to-use liquid, GAMMAGARD LIQUID ERC may help ease the administration burde...

Armis, the cyber exposure management & security company, today announced it has been selected as a launch partner for the Torq AMP alliance program, designed to drive agentic AI innovation. Armis was chosen due to its leading Cyber Exposure Management Platform, Armis CentrixTM, that seamlessly integrates with Torq’s SecOps platform to empower customers and their SOC/Incident Response teams. “As the leader in Cyber Exposure Management, Armis is redefining how organizations understand, prio...